Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
AOMS
Disability trajectories
LOMS
PIRA
POMS
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
23 Aug 2024
23 Aug 2024
Historique:
received:
24
04
2024
accepted:
13
08
2024
revised:
10
08
2024
medline:
24
8
2024
pubmed:
24
8
2024
entrez:
23
8
2024
Statut:
aheadofprint
Résumé
To compare Expanded Disability Status Scale (EDSS) trajectories over time between Multiple Sclerosis (MS) groups with pediatric (POMS), adult (AOMS) and late (LOMS) onset, and between patients with and without progression independent of relapse activity (PIRA). Patients with a first visit within 1 year from onset, ≥ 5-year follow-up and ≥ 1 visit every 6 months were selected from the Italian MS Register. Adjusted disability trajectories were assessed by longitudinal models for repeated measures. Comparisons between groups and between patients with and without PIRA in subgroups were performed by evaluating the yearly differences of mean EDSS score changes versus baseline (delta-EDSS). A first CDA event was defined as a 6-months confirmed disability increase from study baseline, measured by EDSS (increase ≥ 1.5 points with baseline EDSS = 0; ≥ 1.0 with baseline EDSS score ≤ 5.0 and ≥ 0.5 point with baseline EDSS > 5.5). PIRA was defined as a CDA event occurring more than 90 days after and more than 30 days before the onset of a relapse. 3777 MS patients (268 POMS, 3282 AOMS, 227 LOMS) were included. The slope of disability trajectories significantly diverged in AOMS vs POMS starting from the second year of follow-up (Year 2: delta2-EDSS 0.18 (0.05; 0.31), p = 0.0054) and then mean delta2-EDSS gradually increased up to 0.23 (0.07; 0.39, p = 0.004) at year 5. Patients with PIRA had significant (p < 0.0001) steeper increase in EDSS scores than those without PIRA in all groups, although in POMS, the disability trajectories began to diverge later and at a lesser extent with delta-EDSS score of 0.48 vs 0.83 in AOMS and 1.57 in LOMS, at 3 years after the first PIRA. Age is relevant in determining disability progression in MS. POMS shows a less steep increase in EDSS scores over time than older patients. The effect of PIRA in accelerating EDSS progression is less pronounced in POMS than in AOMS and LOMS.
Sections du résumé
BACKGROUND
BACKGROUND
To compare Expanded Disability Status Scale (EDSS) trajectories over time between Multiple Sclerosis (MS) groups with pediatric (POMS), adult (AOMS) and late (LOMS) onset, and between patients with and without progression independent of relapse activity (PIRA).
METHODS
METHODS
Patients with a first visit within 1 year from onset, ≥ 5-year follow-up and ≥ 1 visit every 6 months were selected from the Italian MS Register. Adjusted disability trajectories were assessed by longitudinal models for repeated measures. Comparisons between groups and between patients with and without PIRA in subgroups were performed by evaluating the yearly differences of mean EDSS score changes versus baseline (delta-EDSS). A first CDA event was defined as a 6-months confirmed disability increase from study baseline, measured by EDSS (increase ≥ 1.5 points with baseline EDSS = 0; ≥ 1.0 with baseline EDSS score ≤ 5.0 and ≥ 0.5 point with baseline EDSS > 5.5). PIRA was defined as a CDA event occurring more than 90 days after and more than 30 days before the onset of a relapse.
RESULTS
RESULTS
3777 MS patients (268 POMS, 3282 AOMS, 227 LOMS) were included. The slope of disability trajectories significantly diverged in AOMS vs POMS starting from the second year of follow-up (Year 2: delta2-EDSS 0.18 (0.05; 0.31), p = 0.0054) and then mean delta2-EDSS gradually increased up to 0.23 (0.07; 0.39, p = 0.004) at year 5. Patients with PIRA had significant (p < 0.0001) steeper increase in EDSS scores than those without PIRA in all groups, although in POMS, the disability trajectories began to diverge later and at a lesser extent with delta-EDSS score of 0.48 vs 0.83 in AOMS and 1.57 in LOMS, at 3 years after the first PIRA.
CONCLUSIONS
CONCLUSIONS
Age is relevant in determining disability progression in MS. POMS shows a less steep increase in EDSS scores over time than older patients. The effect of PIRA in accelerating EDSS progression is less pronounced in POMS than in AOMS and LOMS.
Identifiants
pubmed: 39179712
doi: 10.1007/s00415-024-12638-0
pii: 10.1007/s00415-024-12638-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Granziera C, Derfuss T, Kappos L (2023) Time to change the current clinical classification of multiple sclerosis? JAMA Neurol 80(2):128–130
doi: 10.1001/jamaneurol.2022.4156
pubmed: 36534379
Giovannoni G, Popescu V, Wuerfel J et al (2022) Smouldering multiple sclerosis: the “real MS.” Ther Adv Neurol Disord 25(15):17562864211066752
Vollmer TL, Nair KV, Williams IM, Alvarez E (2021) Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve. Neurol Clin Pract 11(4):342–351
doi: 10.1212/CPJ.0000000000001045
pubmed: 34476126
pmcid: 8382415
Kuhlmann T, Moccia M, Coetzee T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22(1):78–88
doi: 10.1016/S1474-4422(22)00289-7
pubmed: 36410373
Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129(Pt 3):606–616
doi: 10.1093/brain/awl007
pubmed: 16415308
Wallin MT, Culpepper WJ, Nichols E et al (2019) Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:269–285
doi: 10.1016/S1474-4422(18)30443-5
Dobson R, Giovannoni G (2019) Multiple sclerosis—a review. Eur J Neurol 26(1):27–40
doi: 10.1111/ene.13819
pubmed: 30300457
Kappos L, Butzkueven H, Wiendl H et al (2018) Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler 24(7):963–973
doi: 10.1177/1352458517709619
pubmed: 28554238
Lublin FD, Häring DA, Ganjgahi H et al (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147–3161
doi: 10.1093/brain/awac016
pubmed: 35104840
pmcid: 9536294
Cree BAC, Hollenbach JA, Bove R et al (2019) Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85(5):653–666
doi: 10.1002/ana.25463
pubmed: 30851128
pmcid: 6518998
Kappos L, Wolinsky JS, Giovannoni G et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132–1140
doi: 10.1001/jamaneurol.2020.1568
pubmed: 32511687
Portaccio E, Bellinvia A, Fonderico M et al (2022) Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain 145(8):2796–2805
doi: 10.1093/brain/awac111
pubmed: 35325059
Iaffaldano P, Portaccio E, Lucisano G, et al. (2023) Multiple sclerosis progression and relapse activity in children. JAMA Neurol. Published online November 27, 2023
Tur C, Carbonell-Mirabent P, Cobo-Calvo Á et al (2023) Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol 80(2):151–160
doi: 10.1001/jamaneurol.2022.4655
pubmed: 36534392
Trojano M, Kalincik T, Iaffaldano P, Amato MP (2022) Interrogating large multiple sclerosis registries and databases: what information can be gained? Curr Opin Neurol 35(3):271–277. https://doi.org/10.1097/WCO.0000000000001057
doi: 10.1097/WCO.0000000000001057
pubmed: 35674068
Iaffaldano P, Lucisano G, Caputo F et al (2021) Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 14:17562864211019574. https://doi.org/10.1177/17562864211019574
doi: 10.1177/17562864211019574
pubmed: 34104220
pmcid: 8170278
Castillo Villagrán D, Yeh EA (2023) Pediatric multiple sclerosis: changing the trajectory of progression. Curr Neurol Neurosci Rep 23(11):657–669
doi: 10.1007/s11910-023-01300-3
pubmed: 37792206
Trojano M, Bergamaschi R, Amato MP et al (2019) The Italian multiple sclerosis register [published correction appears in Neurol Sci. 2019 Apr;40(4):907]. Neurol Sci 40(1):155–165. https://doi.org/10.1007/s10072-018-3610-0
doi: 10.1007/s10072-018-3610-0
pubmed: 30426289
Singer JD, Willett JB (2009) Applied longitudinal data analysis: modeling change and event occurrence. Oxford University Press, New York
Müller J, Cagol A, Lorscheider J, Tsagkas C et al (2023) Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol 80(11):1232–1245. https://doi.org/10.1001/jamaneurol.2023.3331
doi: 10.1001/jamaneurol.2023.3331
pubmed: 37782515
Graves JS et al (2023) Ageing and multiple sclerosis. Lancet Neurol 22(1):66–77
doi: 10.1016/S1474-4422(22)00184-3
pubmed: 36216015
Chitnis T, Aaen G, Belman A et al (2020) Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain 143(9):2733–2741. https://doi.org/10.1093/brain/awaa199
doi: 10.1093/brain/awaa199
pubmed: 32810215
Rivera FJ, de la Fuente AG, Zhao C et al (2019) Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination. Glia 67(8):1510–1525. https://doi.org/10.1002/glia.23624
doi: 10.1002/glia.23624
pubmed: 31038798
pmcid: 6618006
Mostany R, Anstey JE, Crump KL, Maco B, Knott G, Portera-Cailliau C (2013) Altered synaptic dynamics during normal brain aging. J Neurosci 33(9):4094–4104. https://doi.org/10.1523/JNEUROSCI.4825-12.2013
doi: 10.1523/JNEUROSCI.4825-12.2013
pubmed: 23447617
pmcid: 6619332
Zeydan B, Kantarci OH (2020) Impact of age on multiple sclerosis disease activity and progression. Curr Neurol Neurosci Rep 20:24
doi: 10.1007/s11910-020-01046-2
pubmed: 32458308
Trojano M, Liguori M, Bosco Zimatore G et al (2002) Age-related disability in multiple sclerosis. Ann Neurol 51(4):475–480. https://doi.org/10.1002/ana.10147
doi: 10.1002/ana.10147
pubmed: 11921053
Scalfari A (2019) MS progression is predominantly driven by age-related mechanisms. Mult Scler 25(7):902–904
doi: 10.1177/1352458518820633
pubmed: 30747579
Scalfari A, Lederer C, Daumer M, Nicholas R, Ebers GC, Muraro PA (2016) The relationship of age with the clinical phenotype in multiple sclerosis. Mult Scler. 22(13):1750–1758
doi: 10.1177/1352458516630396
pubmed: 26869531
Tremlett H, Zhao Y, Joseph J, Devonshire V, Neurologists UC (2008) Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 79(12):1368–1374
doi: 10.1136/jnnp.2008.145805
pubmed: 18535026
Lorefice L, Ferraro OE, Fenu G et al (2024) Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry. J Neurol. https://doi.org/10.1007/s00415-023-12152-9 . (Published online January 3, 2024)
doi: 10.1007/s00415-023-12152-9
pubmed: 38172380
Lynch S, Baker S, Nashatizadeh M, Thuringer A, Thelen J, Bruce J (2021) Disability measurement in multiple sclerosis patients 55 years and older: what is the expanded disability status scale really telling clinicians? Mult Scler Relat Disord 49:102724
doi: 10.1016/j.msard.2020.102724
pubmed: 33609959
Signori A, Izquierdo G, Lugaresi A et al (2018) Long-term disability trajectories in primary progressive MS patients: a latent class growth analysis. Mult Scler 24(5):642–652
doi: 10.1177/1352458517703800
pubmed: 28382837
Signori A, Lorscheider J, Vukusic S et al (2023) Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. J Neurol Neurosurg Psychiatry 94(1):23–30
doi: 10.1136/jnnp-2022-329987
pubmed: 36171104
Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B (2017) Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 10(8):577. https://doi.org/10.3389/fneur.2017.00577
doi: 10.3389/fneur.2017.00577
Amato MP, Fonderico M, Portaccio E et al (2020) Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain 143(10):3013–3024. https://doi.org/10.1093/brain/awaa251
doi: 10.1093/brain/awaa251
pubmed: 32935843
Baroncini D, Simone M, Iaffaldano P et al (2021) Risk of persistent disability in patients with pediatric-onset multiple sclerosis. JAMA Neurol 78(6):726–735. https://doi.org/10.1001/jamaneurol.2021.1008
doi: 10.1001/jamaneurol.2021.1008
pubmed: 33938921
Mosconi P, Guerra T, Paletta P et al (2023) Data monitoring roadmap. The experience of the Italian multiple sclerosis and related disorders register. Neurol Sci. 44(11):4001–4011. https://doi.org/10.1007/s10072-023-06876-9
doi: 10.1007/s10072-023-06876-9
pubmed: 37311951
pmcid: 10264214